New England Compounding Pharmacy, Inc.  Bankruptcy New Filing Alert: Response To The Motion For A Protective Order/To File A Pleading Under Seal

On June 13, 2014, a response to the motion for a protective order/to file a pleading under seal was filed in the bankruptcy case of New England Compounding Pharmacy, Inc.  and its affiliates.

The filing was assigned docket number 831 and is described on the court’s official docket as follows:

Response with certificate of service filed by Interested Party Insight Health Corp. Re: [791] Expedited Motion filed by Creditor Committee Official Committee of Unsecured Creditors Authorizing Counsel to Provide its Members with Information from Plaintiffs’ Proof of Claim Supporting Documentation with certificate of service., [816] Expedited Motion filed by Interested Party Lead Counsel for Plaintiffs’ Steering Committee For Order – Motion by Lead Counsel in MDL 2419 for an Order Authorizing Members of the Plaintiffs’ Steering Committee to Receive Access to Info (Clancy, David)

New England Compounding Pharmacy, Inc.  filed for bankruptcy protection, or had an involuntary bankruptcy petition filed against it, on December 21, 2012. The bankruptcy case is pending before the United States Bankruptcy Court for the District of Massachusetts. The case number for the lead bankruptcy case is 12-19882. The bankruptcy case is currently assigned to United States Bankruptcy Judge Henry Boroff. The law firm of Murtha Cullina LLP is acting as lead bankruptcy counsel to New England Compounding Pharmacy, Inc.  in the bankruptcy case.

* * * * * * * * * * * * * * * * * * * *

Chapter 11 Dockets is the most efficient, effective way to research bankruptcy cases and identify precedent.

Because it was designed by experienced restructuring professionals and is chapter 11 specific in focus, Chapter 11 Dockets is optimized for the unique needs of bankruptcy practitioners.

Learn more and sign up for a free trial by visiting http://info.chapter11dockets.com/about-chapter-11-dockets

* * * * * * * * * * * * * * * * * * * *

Leave a Reply